Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks
Details : Nexletol(bempedoic acid) is an adenosine triphosphate-citrate lyase inhibitor indicated as an adjunct to diet and statin therapy for heart attack, hypercholesterolaemia & cardiovascular diseases.
Product Name : Nexletol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2024
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Daiichi Sankyo
Deal Size : $1,255.0 million
Deal Type : Collaboration
Esperion and Daiichi Sankyo Amend $125M Collaboration, Resolve Litigation
Details : The collaboration combines Esperion Therapeutics’ NILEMDO (bempedoic acid), an ACL inhibitor, with Daiichi Sankyo’s commercial capabilities for cardiovascular medicines.
Product Name : Nilemdo
Product Type : Other Small Molecule
Upfront Cash : $30.0 million
March 01, 2024
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Daiichi Sankyo
Deal Size : $1,255.0 million
Deal Type : Collaboration
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nexletol (bempedoic acid) is indicated as an adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lower...
Product Name : Nexletol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 19, 2022
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL
Details : NEXLETOL (bempedoic acid) is indicated as an adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lower...
Product Name : Nexletol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2022
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Daiichi Sankyo
Deal Size : $1,130.0 million
Deal Type : Partnership
Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories
Details : The agreement combines Esperion Therapeutics’ first-in-class ATP Citrate Lyase (ACL) inhibitor, bempedoic acid, with Daiichi Sankyo’s commercial capabilities, as well as synergies with their existing portfolio of cardiovascular medicines.
Product Name : Nexlizet
Product Type : Other Small Molecule
Upfront Cash : $30.0 million
April 26, 2021
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Daiichi Sankyo
Deal Size : $1,130.0 million
Deal Type : Partnership
Lead Product(s) : Bempedoic Acid,Atorvastatin,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The aim of this Phase 2 study was to evaluate LDL-C lowering when NEXLETOL was initiated together with ezetimibe (10 mg) and atorvastatin (20 mg), as compared with placebo.
Product Name : Nexletol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2021
Lead Product(s) : Bempedoic Acid,Atorvastatin,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : H.C. Wainwright & Co
Deal Size : $225.0 million
Deal Type : Public Offering
Esperion Announces Pricing of $225 Million Public Offering
Details : Esperion intends to use the net proceeds from the offering to fund the ongoing commercialization efforts for NEXLETOL and NEXLIZET, research and clinical development of current or additional pipeline candidates, and general corporate purposes.
Product Name : Nexletol
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 12, 2021
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : H.C. Wainwright & Co
Deal Size : $225.0 million
Deal Type : Public Offering
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Esperion to Present Key Science at the American Heart Association Scientific Sessions 2021
Details : Bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of ...
Product Name : Nexlizet
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2021
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Both analyses demonstrated significant lowering of low-density lipoprotein cholesterol (LDL-C) by NEXLETOL® (bempedoic acid) Tablets by week 12 in specific subgroups, including people who cannot tolerate statins and females, compared to placebo.
Product Name : Nexletol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 13, 2020
Lead Product(s) : Bempedoic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NUSTENDI is approved for patients who require additional Ldl-Cholesterol lowering on a background statin, other lipid-lowering therapies, or considered statin intolerant.
Product Name : Nustendi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 04, 2020
Lead Product(s) : Bempedoic Acid,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable